Navigation Links
Diet Pill Meridia Ups Heart Attack Risk: Study
Date:9/2/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Sept. 1 (HealthDay News) -- A new study is linking the popular weight loss drug Meridia to an increased risk of non-fatal heart attacks and stroke, although taking the drug did not seem to up the risk of death in patients with a history of heart problems.

The finding is stirring mixed reactions from experts.

According to the authors of the trial, which was funded by Meridia's maker, Abbott, the findings are generally in line with what has been known about the drug and shouldn't change how it is used.

"The only time you've got an increase in heart attacks or strokes were in those patients who had had previous heart disease or strokes, in other words, the people who . . . should never have received the drug in the first place," said Dr. Philip T. James, a professor at the London School of Hygiene and Tropical Medicine in England, and first author on the paper, which appears in the Sept. 2 issue of the New England Journal of Medicine.

Since January, Meridia (sibutramine), has carried a label warning that it should not be used by people with preexisting heart disease, so "the current prescription is entirely appropriate," James said.

However, not everyone agrees. The U.S. Food and Drug Administration is slated to meet in September to decide if more regulatory action -- perhaps a tougher "black-box" warning or even removing Meridia from the market -- should be taken.

According to Dr. Greg Curfman, executive editor of the NEJM and co-author of an accompanying editorial, the FDA's January warning was based on preliminary information only. The new study results represent the first hard data, "the first outcomes trial," he said.

Based on the findings, he and others wonder if the drug is worth keeping around.

The drug did not seem to make people healthier, Curfman said. "Some people were actually made worse," he said. "All this taken together results in an unfavorable risk-benefit profile and, based on that, we don't see a rationale for keeping this on the market."

Also, he said, "the efficacy of producing weight loss with the drug is very unimpressive. In this trial, patients lost on average less than 4 kilograms [about 9 pounds] and we know that that's not going to translate into a real health benefit over time. It's not enough weight loss. The FDA has a benchmark of about 5 percent loss of baseline body weight to consider a weight loss drug [effective]."

A University of Rochester expert concurs.

"I have never really found that people taking Meridia had obtained a real substantive weight loss," said Dr. J. Chad Teeters, assistant professor of clinical medicine, cardiology division at the University of Rochester Medical Center. "It seems that a lot of these 'quick fix' weight loss drugs don't really live up to the hype and they come with risks. I think there's probably going to be a significant downturn in the use of the drug given the low efficacy and increased risk of side effects."

This trial involved almost 11,000 older overweight or obese adults with type 2 diabetes or heart disease or both who were randomized either to take Meridia or a placebo and followed for about 3.4 years.

In the group taking Meridia, 11.4 percent had a heart attack, stroke or died as the result of a heart problem, versus 10 percent in the control group, a 16 percent increase.

People taking Meridia also had a 28 percent higher risk for nonfatal heart attack and a 36 percent raised risk for nonfatal stroke, compared to those taking placebo, the authors found.

All trial participants were also engaged in a diet-and-exercise program to lose weight, whether they were taking the drug or not, said study author James. "Meridia is not a wonder drug that guarantees people lose weight but it is a major additional help for people who change their diet and increase their physical activity," he said.

But Teeters narrowed the prescription. "Good old-fashioned diet and exercise is the only substantive sustained therapy that's shown to be helpful," he said. "There's no quick-fix pill."

More information

There's more on Meridia at the U.S. National Library of Medicine.

SOURCES: Philip T. James, M.D., D.Sc., professor, London School of Hygiene and Tropical Medicine, U.K.; Chad Teeters, M.D., assistant professor, clinical medicine, cardiology division, University of Rochester Medical Center; Greg Curfman, M.D., executive editor, Sept. 2, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DASH Diet Shown to Lower Heart Attack Risk Almost 20%
2. Clinic puts patients at heart of multiple sclerosis research
3. Heart attacks jump in young Italian women
4. Combining resistance and endurance training best for heart health
5. Heart disorder hits national epidemic proportions
6. Going live to the beating heart
7. Low-Dose Omega-3 Fatty Acids Dont Protect Heart Patients
8. Heart Risks the Same With 2 Diabetes Drugs: Study
9. Math from the heart: Simulating stent design and coating
10. Innovative imaging system may boost speed and accuracy in treatment of heart rhythm disorder
11. Deaths From Heart Attack Rise With Delays in Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Diet Pill Meridia Ups Heart Attack Risk: Study 
(Date:7/21/2017)... NEW ORLEANS, La. (PRWEB) , ... July 21, ... ... tool to allow 4th-year medical students improve their chances of acceptance to a ... particularly for those who have earned degrees outside the U.S. , According to ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... insight into why concussion rates are on the rise, say researchers presenting their ... today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: